IL1B and neoplasm: Nevertheless, the combination of anti-PD-1 and anti-IL-1β treatments (Table S5) resulted in similar modulations of the cytokine/chemokine ligand-receptor interactions as compared to anti-IL-1β treatment (Table S1) in the KPC-4545 tumor.